Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

President Donald Trump's executive order mandates drugmakers to lower prices to match those in affluent nations, threatening ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

The executive order would require other countries to pay more for medications so that Americans could pay less. But experts ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United ...

The film “Lilly,” a biopic about the equal pay icon Lilly Ledbetter, lands in theaters at a difficult time for her biggest ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

"Why don't we try to fix those issues? If you can do that, you'd get much better outcomes", he adds. On whether victims are being properly protected, he says the government needs to find a "long ...